Wedbush Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $9

Benzinga · 2d ago
Wedbush analyst David Nierengarten maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $25 to $9.